NY-ESO-1 T Cells in OG Cancer (ATTACK-OG)
A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer
Sponsor: Erasmus Medical Center
Terminated
Withdrawal of funding
Listed as NCT01795976, this PHASE2 trial focuses on Oesophageal Cancer and remains terminated or withdrawn. Sponsored by Erasmus Medical Center, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Erasmus Medical Center
- Fiona Thistlethwaite
- Karolinska University Hospital
- Ospedale San Raffaele
- The Christie NHS Foundation Trust
- The Netherlands Cancer Institute
- University College London Hospitals
For direct contact, visit the study record on ClinicalTrials.gov .